Yungjin Pharm. Co., Ltd. (KRX:003520)
2,020.00
+20.00 (1.00%)
Dec 11, 2025, 3:30 PM KST
Yungjin Pharm. Revenue
Yungjin Pharm. had revenue of 38.98B KRW in the quarter ending September 30, 2013, with 4.67% growth. This brings the company's revenue in the last twelve months to 158.79B, up 23.36% year-over-year. In the year 2012, Yungjin Pharm. had annual revenue of 137.69B with 22.82% growth.
Revenue (ttm)
158.79B
Revenue Growth
+23.36%
P/S Ratio
2.33
Revenue / Employee
276.63M
Employees
574
Market Cap
369.44B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2012 | 137.69B | 25.58B | 22.82% |
| Dec 31, 2011 | 112.11B | -4.21B | -3.62% |
| Dec 31, 2010 | 116.32B | 12.94B | 12.52% |
| Dec 31, 2009 | 103.38B | -7.53B | -6.79% |
| Dec 31, 2008 | 110.91B | 1.25B | 1.14% |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 1999 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |